To include your compound in the COVID-19 Resource Center, submit it here.

Target enzyme undetected at week 16 in Sangamo's MPS II gene editing trial

Sangamo Therapeutics Inc. (NASDAQ:SGMO) reported data showing that plasma iduronate 2-sulfatase (IDS) activity was below the level of quantification through 16 weeks in the Phase I/II CHAMPIONS trial evaluating SB-913 to treat mucopolysaccharidosis II (MPS II, Hunter’s syndrome).

SB-913 is a zinc finger nuclease (ZFN)-mediated gene editing therapy that is

Read the full 490 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE